Fresh analysis suggests that people who stop using blockbuster GLP-1 drugs like Wegovy and Mounjaro may regain shed pounds far faster than those who end traditional lifestyle plans.
Findings released in a major health publication demonstrates that while overweight individuals often shed substantial amounts of their body weight while on the medication, the mass returns at an average rate of nearly a kilo each month upon discontinuation.
"People buying such drugs should be aware of the risk of quick rebound weight gain when the medication concludes," stated researcher Dr. Susan Jebb.
Such speed of recovery suggests a reversion to pre-treatment mass within about 18 months.
Weighing Treatments
The analysis, which looked at dozens of trials involving thousands of participants, contrasted the outcomes of the injectable medications with conventional dieting.
Scientists note that individuals who lose weight through diet and exercise typically experience a slower creep back—around 100 grams monthly—once they finish.
Explaining the Rapid Rebound
Experts propose the mode of action of the injections explains the amplified weight return.
GLP-1 drugs mimic a body's own chemical called glucagon-like peptide-1, which moderates hunger.
"Sustained high doses of GLP-1 concentrations several times higher than the body's typical production might result in the system to generate a reduced amount of its own natural GLP-1, and could reduce responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this hormone supplement leads to appetite is unsuppressed, making excessive eating much more probable."
A Lifelong Condition?
Medical guidelines recommend the jabs for individuals with obesity-related medical conditions, alongside recommended diet and exercise modifications.
A number of clinicians contend that, due to the likelihood of weight regain, the treatment might need to be long-term.
This perspective is reinforced by drug manufacturers, who state that the results "emphasize the chronic character of obesity," akin to managing conditions like diabetes.
Patient Experiences
Users who have discontinued the jabs explain a intense resurgence of hunger.
"It was like something activating and you become extremely hungry," said a patient.
This challenge is exacerbated if individuals have not adopted permanent lifestyle or habit changes during therapy.
Significant Interest
Figures indicate that millions of people in the UK have tried these injections in the past year, with demand continuing to grow.
- Adoption is higher among women compared to men.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the medications through private healthcare rather than the NHS.
Finally, experts emphasize that while GLP-1 drugs are potent agents for shedding pounds, they are not a magic fix and lasting health benefits hinges on integrated behavioural management.
